Histogen currently anticipates meeting the following upcoming development milestones: File an Investigational New Drug Application Amendment in Second Quarter 2020 and initiate a Phase 1b/2a study of HST 001 for the treatment of male pattern baldness in Second Quarter 2020. File an Investigational Device Exemption in Second Quarter 2020 and initiate a Phase 1 study of HST 002 as a dermal filler in Second Quarter 2020. File an Investigational New Drug Application in Third Quarter 2020 and initiate a Phase 1 study of HST 003 for the treatment of articular cartilage defects in the knee in Third Quarter 2020. Announce top-line results from Phase 1 study of HST 002 for the treatment of nasolabial folds in Third Quarter 2020. Announce top-line results from Phase 1b/2a study of HST 001 for the treatment of male pattern baldness in Fourth Quarter 2020.